Profitable international savings expert Hansard Global offers a secure yield underpinned by strong cash flows as well as scope for growth on good margins. Yet in spite of its excellent trading record and income credentials, its shares languish at a curious discount to ‘embedded value’.
Floated on the Full List at the end of 2006 and operating out of the Isle of Man and Irish Republic, Hansard is a specialist long-term savings provider, offering tax-efficient, flexible investment products, within a life assurance policy wrapper, designed to attract affluent investors across the globe.
Its low-risk business model involves distribution of products through financial services intermediaries, IFAs or the retail arms of financial institutions. Truly global in scope, the company has more than 540 intermediaries servicing over 43,000 policyholders in 170 or more countries. Its ‘Hansard OnLine’ web platform offers IFAs support and efficiency and enables high net-worth individuals (HNWIs) to view their policies and investment performance ‘24/7’.
‘Simply put, we make money’, enthuses CFO Vince Watkins. ‘All we do is get intermediaries to write business for us.’ Making money from fees and commissions from initial investments, fund switching and investment administration, Hansard is after margin rather than volume and enjoys both regular premium and single premium (one-off lump sum) business. ‘We won’t write business if it is not profitable’, Watkins adds.
Regular premiums are more profitable than single premiums and offer high levels of repeat business. This is because, although clients can– and do – switch their investments, the appeal of the life wrapper means they rarely change administrator.
Watkins does concede that recent rumblings in financial markets have slowed the single premium business short term, although the market will inevitably come back: ‘In these volatile markets, people are reluctant to invest.’
Annual numbers to June demonstrated Hansard’s robustness, with pre-tax profits improving to £23.6 million (2007: £19.7 million) and assets under administration holding up at £1.14 billion.
Significantly, the “European embedded value (EEV)” of the group grew by 11.5 per cent to £243 million. This growth in EEV, an insurance industry metric for valuing businesses based on discounted cash flow, meant EEV per share increased to 177.1p (2007: 158.8p), well north of the current share price. And while new business reduced to £33.7 million (2007: £35.5 million), new business margins held up at 7.8 per cent (2007: 8.3 per cent).
Having swelled EPS by more than 18 per cent to 17p, Hansard Global, which had already paid out a £6.9 million special dividend during the year, lifted the final dividend by a penny to 7p, for a 20 per cent hike in the total payout to 12p per share. Strongly cash generative – Hansard closed the year with almost £60 million cash in the coffers – the company looks to pay out 70 per cent of its post-tax profits in dividends and further special dividends could be on the cards.
Short-term volatility represents a challenge for Hansard, although positive trends play into the hands of the group, whose ‘biggest markets are South America – Brazil, Mexico, Argentina – and Taiwan in the Far East’. As of December last year, global HNWI wealth totalled US$40.7 trillion, up 10 per cent year on year, with average HNWI wealth surpassing $4 million for the first time ever. Moreover, emerging markets, in particular Latin America and the Middle East (an area on which management is giving increasing focus) scored the greatest regional HNWI gains in terms of population, which augurs well for the group’s growth in these regions.
A growth company with serious income credentials, shares in Hansard have fallen from a 52-week peak of 286.75p to just 123p, with illiquidity one possible factor constraining its rating.
Nevertheless, investors able to get their hands on the shares, which should trade at a premium rather than a discount to embedded value, should do so, joining the likes of Schroder Investment and F&C Asset Management on the shareholder list.
Growth Company Investor is the leading magazine for investors in AIM and boasts award-winning research and analysis coverage.
Subscribe now and receive a 50% discount
Advertisement
Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.
M&A on AIM 2009 is a unique and wide-ranging examination of merger and acquisition activity on AIM over the past 12 months, with an analysis of all the acquisitions, disposals, takeovers and delistings on AIM, including
canvassing the opinions of some of the major M&A powerbrokers. To order click here.
Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.
Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.
The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today and benefit from a £10 discount!
This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Fast-growing Alliance Pharma is to buy most of Cambridge Laboratories' trade and assets for £14.3m and £16.4m.
Investors seeking to back a business with exceptionally high earnings visibility and a burgeoning order book should look no further than Norwich-based infrastructure services specialist May Gurney.
Staff rostering software specialist Allocate, buoyed by 27% organic growth in the six months to November, aims to speed expansion with several acquisitions in coming years.